The role of neuroendocrine cells in prostate cancer: A comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities

Current Medicinal Chemistry

Volumn 21, Issue 9, 2014, Pages 1082-1092

  Lugnani, F ^a   Simone, G ^b   Biava, P M ^c   Ablin, R J ^d  

^a Kirurski Sanatorij   (Slovenia)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cryoablation of prostate cancer; Cryoimmunomodulation; Epigenetic therapy; Focal ablation prostate cancer; Hormonal deprivation; Neuroendocrine; Prostate cancer; Prostate cancer stem like cells; Prostate cancer surgery; Targeted therapies

Indexed keywords

ABLATION THERAPY; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CRYOSURGERY; EMBASE; EPIGENETICS; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOGENESIS; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MEDLINE; NEUROENDOCRINE PROSTATE CANCER; NEUROSECRETORY CELL; PHOTODYNAMIC THERAPY; PROSTATE CANCER; SURVIVAL RATE;

ANIMALS; CRYOSURGERY; EPIGENESIS, GENETIC; HUMANS; MALE; NEUROENDOCRINE CELLS; PHOTOCHEMOTHERAPY; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896374837     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131201143752     Document Type: Article

References (85)

1. Boyle, P.; Ferlay, J. Cancer incidence and mortality in Europe 2004. Ann. Oncol., 2005, 16, 481-488. (Pubitemid 40458328)
2. Mazzucchelli, R.; Morichetti, D.; Lopez-Beltran, A.; Cheng, L.; Scarpelli, M.; Kirkali, Z.; Montironi, R. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. B. J. U. Int., 2009, 103, 1464-1470.
3. Ritchie, C. K.; Thomas, K. G.; Andrews, LR.; Tindall, D. J.; Fitzpatrik, L. A. Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate, 1997, 30, 183-187. (Pubitemid 27149277)
4. Iwamura, M.; Wu, G.; Abrahamsson, P. A.; Di Sant'Agnese, P.; Cockett, A. T. K.; Deftos, L. J. Prathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology, 1994, 43, 667-674.
5. Abrahamsson, P. A.; Falkmer, S.; Falt, K.; Grimelius, L. The course of neuroendocrine differentiation in prostatic carcinomas. Pathol. Res. Pract., 1989, 185, 373-380.
6. Bonkhoff, H.; Wernert, N.; Dhom, G.; Remberger, K. Relation of endocrine-paracrine cells to proliferation in normal, hyperplastic, neoplastic human prostate. Prostate, 1991, 19, 91-98.
7. Abrahamsson, P. A.; Wadstrom, L. B.; Alumets, J.; Falkmer, S.; Grimelius, L. Peptide hormoneand serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Path. Res. Pract., 1989, 185, 373-380.
8. Aprikian, A.; Han, K.; Guy, L.; Landry, F.; Begin, L. R.; Chevalier, S. Neuroendocrine differentiation and bombesin/gastrin-releaseing peptide family of neuropeptides in the progress of human prostate cancer. Prostate Suppl., 1998, 82, 738-743.
9. Harper, M. E.; Glynne-Jones, E.; Goddard, L.; Thurston, V. J.; Griffiths, K. Vascular endothelial growth factor (VEGF) expression in prostatic tumors and its relationship to neuroendocrine cells. Br. J. Cancer, 1996, 74, 910-916. (Pubitemid 26319324)
10. Di Sant'Agnese, P.; De Mesy Jensen, K. Somatostatin and somatostatinlike immunoreactive endocrine-paracrine cells in the human prostate gland. Arch. Pathol. Lab. Med., 1984, 108, 693-696. (Pubitemid 14062017)
11. Hvamstad, T.; Jordal, A.; Hekmat, N.; Paus, E.; Fossa, S. D. Neuroendocrine Serum Tumour Markers in Hormone-Resistant Prostate Cancer. Eur. Urol., 2003, 44, 215-221. (Pubitemid 36917006)
12. Ablin, R. J.; Whyard, T. C. Immunobiological implications of select bioactive molecules in the prostate. pp. 149-85. In: Farnsworth WE and Ablin R. J. (Eds): The Prostate as an Endocrine Gland. CRC Press, Baca Raton, FL, 1990.
13. Aumuller, G.; Leonhardt, M.; Janssen, M.; Konrad, L.; Bjartell, A.; Abrrahamsson, P. A. Nerogenic origin of human prostate endocrine cells. Urology, 1999, 78, 256-264.
14. Terada, T. Small cell neuroendocrine carcinoma of the prostate: incidence and a report of four cases with an examination of KIT and PDFFRA. Prostate, 2012, 72, 1150-1156.
15. Grobholz, R.; Bohrer, M. H.; Siegsmund, M.; Junemann, K. P.; Bleyl, U.; Woenckhaus, M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol. Res. Pract., 2000, 196, 277-284. (Pubitemid 30313232)
16. Di Sant'Agnese, P. A.; Cockett, A. T. K. Neuroendocrine differentiation in prostatic malignancy. Cancer, 1996, 78, 357-361. (Pubitemid 26234584)
17. Sciarra, A.; Mariotti, G.; Gentile, V.; Voria, G.; Pastore, A.; Monti, S.; Di Silverio, F. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? B. J. U. Int., 2003, 91, 438-445. (Pubitemid 36359624)
18. Welbourn, R. B. Current status of the apudomas. Ann. Surg., 1977, 185, 1-12. (Pubitemid 8015183)
19. Pearse, A. G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J. Histochem. Cytochem., 1969, 17, 303-313.
20. Pearse, A. G.; Pollak J. M.; Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas. Gut., 1971, 12, 783-788.
21. Zenzmaier, C.; Untergasser, G.; Berger, P. Aging of the prostate epithelial stem/progenitor cell. Exp. Gerontol., 2008, 43, 981-985.
22. Ousset, M.; Van Keymeulen, A.; Bouvencourt, G.; Sharma, N.; Achouri, Y.; Simons, B. D.; Blanpain, C. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat. Cell. Biol., 2012, 14, 1131-1118.
23. Amin, M. B.; McKenney, J. K.; Tickoo, S. K.; Paner, G. P.; Shen, S. S.; Velazquez, E. F.; Cubilla, A. L.; Ro, J. Y.; Reuter, V. E. Diagnostic pathology Genitourinary. Amirsys, 2010, 114-117.
24. Deng, X.; Liu, H.; Huang, J.; Cheng, L.; Keller, E. T.; Parsons, S. J.; Hu, C. D. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res., 2008, 68, 9663-9670.
25. Hirano, D.; Okada, Y.; Minei, S.; Takimoto, Y.; Nemoto, N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol., 2004, 45, 586-592. (Pubitemid 38481685)
26. Cox, M. E.; Deeble, P. D.; Lakhani S.; Parsons, S. J. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res., 1999, 59, 3821-3830. (Pubitemid 29381892)
27. Lee, S. O.; Chun, J. Y.; Nadiminty, N.; Lou, W.; Gao, A. C. IL-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 15, 764-773. (Pubitemid 46709445)
28. Wu, J. T.; Astill, M. E.; Liu, G. H.; Stephenson, R. A. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J. Clin. Lab. Anal., 1998, 12, 20-25. (Pubitemid 28079998)
29. Isshiki, S,.; Akakura, K.; Komiya, A.; Suzuki, H.; Kamiya, N.; Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J. Urol., 2002, 167, 512-515. (Pubitemid 34074517)
30. Yashi, M.; Muraishi, O.; Kobayashi, Y, Tokue, A,; Nanjo, H. Elevated serum progastrin-releasing peptide in metastatic and androgen-independent prostate cancer patients. Prostate, 2002, 51, 84-97.
31. Tarle, M.; Frkovic-Grazio, S.; Kraljic, I.; Kovacic, K. A more objective staging of advanced prostate cancer-routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. Prostate, 1994, 24, 143-148. (Pubitemid 24109595)
32. Sasaki, T.; Komiya A.; Suzuki, H.; Shimbo, M.; Ueda, T.; Akakura, K.; Ichikawa, T. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur. Urol., 2005, 48, 224-229. (Pubitemid 40957093)
33. Hirano D.; Okada Y.; Minei S.; Takimoto Y.; Nemoto N. Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen DeprivationTherapy. Eur. Urol., 2004, 45, 586-92. (Pubitemid 38481685)
34. Vashchenko, N.; Abrahamsson, P. A. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur. Urol., 2005, 47, 147-155. (Pubitemid 40126970)
35. Ferrero-Poüs, M.; Hersant, A. M.; Pecking, A.; Bresard-Leroy, M.; Pichon, M. F. Serum Chromogranin A in advanced prostate cancer. B. J. U. Int., 2001, 88, 790-796.
36. Kamiya, N.; Suzuki, H.; Kawamura, K.; Imamoto, T.; Naya, Y.; Tochigi, N.; Kakuta, Y.; Yamaguchi, K.; Ishikura, H.; Ichikawa, T. Neuroendocrine differentiation in stage D2 prostate cancers. Int. J. Urol., 2008, 15, 423-428. (Pubitemid 351623888)
37. Kamiya, N, Akakura, K, Suzuki, H et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur. Urol., 2003, 44, 309-314. (Pubitemid 37051698)
38. Jeetle, S. S.; Fisher, G.; Yang, Z. H.; Stankiewicz, E.; Møller, H.; Cooper, C. S.; Cuzick, J.; Berney, D. M.; Trans-Atlantic Prostate Group. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch., 2012, 461, 103-107.
39. Dahm, P.; Yeung, L. L.; Gallucci, M.; Simone, G.; Schunemann, H. J. How to use a clinical practice guideline. J. Urol., 2009, 181, 472-479.
40. Heidenreich, A.; Bellmunt, J.; Bolla, M.; Joniau, S.; Mason, M.; Matveev, V.; Mottet, N.; Schmid, H. P.; van der Kwast, T.; Wiegel, T.; Zattoni, F.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol., 2011, 59, 61-71.
41. Bianco, F. J.; Scardino, P. T.; Eastham, J. A. Radical Prostatectomy: long-term cancer control and recovery of sexual and urinary function "trifecta". Urology, 2005, 66, 83-94. (Pubitemid 41356564)
42. Simone, G.; Papalia, R.; Ferriero, M.; Guaglianone, S.; Gallucci, M. Laparoscopic "single knot-single running" suture vesicourethral anastomosis with posterior musculofascial reconstruction. World. J. Urol., 2012, 30, 651-657.
43. Naselli, A.; Simone, G.; Papalia, R.; Gallucci, M.; Introini, C.; Andreatta, R.; Puppo, P. Late-onset incontinence in a cohort of radical prostatectomy patients. Int. J. Urol., 2011, 18, 76-79.
44. Stephenson, A. J.; Kattan, M. W.; Eastham, J. A.; Bianco, F. J. Jr.; Yossepowitch, O.; Vickers, A. J.; Klein, E. A.; Wood, D. P.; Scardino, P. T. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol., 2009, 27, 4300-4305.
45. Ward, J. F.; Slezak, J. M.; Blute, M. L.; Bergstralh, E. J.; Zincke, H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. B. J. U. Int., 2005, 95, 751-756. (Pubitemid 40547200)
46. D'Amico, A.; Renshaw, A. A.; Loffredo, M.; Kantoff, P. W. Androgen suppression and radiation vs radiation alone for prostate cancer; a randomized controlled trial. J. A. M. A., 2008, 299, 289-295. (Pubitemid 351159365)
47. Bolla, M.; De Reijke, T. M.; Van Tienhoven, G.; Van den Bergh, A. C.; Oddens, J.; Poortmans, P. M.; Gez, E.; Kil, P.; Akdas, A.; Soete, G.; Kariakine, O.; Van der Steen-Banasik, E. M.; Musat, E.; Piérart, M.; Mauer, M. E.; Collette, L.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med., 2009, 360, 2516-2527.
48. Zelefsky, M. J.; Eastham, J. A.; Cronin, A. M.; Fuks, Z.; Zhang, Z.; Yamada, Y.; Vickers, A.; Scardino, P. T. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J. Clin. Oncol., 2010, 28, 1508-1513.
49. Arcangeli, G,.; Strigari, L.; Arcangeli, S.; Petrongari, M. G,.; Saracino, B.; Gomellini, S.; Papalia, R.; Simone, G.; De Carli, P.; Gallucci, M. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 975-982.
50. Ablin, R. J.; Mason, M. D. (Eds.): Metastasis of Prostate Cancer. Springer, Dordrecht, The Netherlands, 2008, pp. 407.
51. Lukka, H.; Waldron, T.; Chin, J.; Mayhew, L.; Warde, P.; Winquist, E.; Rodrigues, G.; Shayegan, B. High-intensity focused ultrasound for prostate cancer: a systematic review. Clin. Oncol. (R. Coll. Radiol.), 2011, 23, 117-127.
52. Cordeiro, E. R.; Cathelineau, X.; Thüroff, S.; Marberger, M.; Crouzet, S.; De la Rosette, J. J. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. B. J. U. Int., 2012, 110, 1228-1242.
53. Gonder, M. J.; Soanes, W. A.; Smith, V. Experimental prostate cryosurgery. Invest. Urol., 1964, 1, 610-9.
54. Soanes, W. A. Cryosurgery on prostate reported. J. A. M. A., 1966, 196, Suppl, 29.
55. Sesia, G.; Ferrando, U.; Riggi, G. A new apparatus for use in the cryotherapy of prostate obstruction. Int. Surg., 1968, 49, 330-338.
56. Reuter, H. Cryosurgery in operations on the prostate. Urol. Int., 1969, 24, 145-152.
57. Ablin, R. J.; Soanes, W. A.; Gonder, MJ. Immunologic studies of the prostate. A review. Int. Surg., 1969, 52, 8-21.
58. Soanes, W. A.; Ablin, R. J.; Gonder, M. J. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J. Urol., 1970, 104, 154-159.
59. Ablin, R. J.; Gonder, M. J.; Soanes, W. A. Elution of cell-bound antiprostatic epithelial antibodies after multiple cryotherapy of carcinoma of the prostate. Cryobiology, 1974, 11, 218-221.
60. Ablin, R. J.; Cryoimmunotherapeutic Study Group. Cryosensitivity. Factors influencing development of immunologic response following cyrosurgery of prostate. Urology, 1975, 5, 317-21.
61. Gonder, M. J. Cryosurgery in prostate carcinoma: clinical evidence of immunostimulation of host versus tumor. Natl. Cancer Inst. Monogr., 1978, 369. (Pubitemid 9141867)
62. Reuter, H. J.; Reuter, M. 20 years of prostate surgery. Reduction in the number of complications through application of a new concept in TUR, cryosurgery and surgical procedures. J. Urol. Nephrol., 1980, 73(4), 279-290. (Pubitemid 10088844)
63. Bahn, D. K.; Lee, F.; Badalament, R.; Kumar, A.; Greski, J.; Chernick, M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology, 2002, 60(2 Suppl 1), 3-11. (Pubitemid 36153108)
64. Cohen, J. K.; Miller, R. J. Jr.; Ahmed, S.; Lotz, M. J.; Baust, J. Tenyear biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology, 2008, 71, 515-518. (Pubitemid 351374703)
65. Jones, J. S.; Rewcastle, J. C.; Donnelly, B. J.; Lugnani, F. M.; Pisters, LL.; Katz, AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J. Urol., 2008, 180, 554-558.
66. Ablin, R. J. An appreciation and realization of the concept of cryoimmunology, pp. 136-54. In Onik GM, Rubinsky B, Watson G, Ablin RJ (Eds): Percutaneous Prostate Cryoablation. Quality Medical Publishing, Inc., St. Louis, MO, 1995.
67. Caso, J. R.; Tsivian, M.; Mouraviev, V.; Kimura, M.; Polascik, T. J. Complications and postoperative events after cryosurgery for prostate cancer. B. J. U. Int., 2012, 109, 840-845.
68. Malcolm, J. B.; Fabrizio, M. D.; Barone, B. B.; Given, R. W.; Lance, R. S.; Lynch, D. F.; Davis, J. W.; Shaves M. E.; Schellhammer P. F. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. J. Urol., 2010, 183, 1822-1828.
69. Udagawa, M.; Kudo-Saito, C.; Hasegawa, G.; Yano, K.; Yamamoto, A.; Yaguchi, M.; Toda, M.; Azuma, I.; Iwai, T.; Kawakami, Y. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin. Cancer Res., 2006, 12, 7465-7475. (Pubitemid 46095422)
70. Den Brok, M. H.; Sutmuller, R. P.; Nierkens, S.; Bennink, E. J.; Frielink, C.; Toonen, L. W.; Boerman, O. C.; Figdor, C. G.; Ruers, T. J.; Adema, G. J. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br. J. Cancer, 2006, 95, 896-905. (Pubitemid 44498106)
71. International Society for Cellular Therapy. Dendritic Cells: A Basic Review. http://www.celltherapysociety.org/files/PDF/Resources/OnLine-De ndritic-Education-Brochure.pdf (Last updated May 2003)
72. Levy, M. Y.; Sidana, A.; Chowdhury, W. H.; Solomon, S. B.; Drake, C. G.; Rodriguez, R.; Fuchs, E. J. Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J. Pharmacol. Exp. Ther., 2009, 330, 596-601.
73. Machlenkin, A.; Goldberger, O.; Tirosh, B.; Paz, A.; Volovitz, I.; Bar-Haim, E.; Lee, S. H.; Vadai, E.; Tzehoval, E.; Eisenbach, L. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin. Cancer Res., 2005, 11, 4955-4961. (Pubitemid 41557217)
74. Biava, P. M.; Bonsignorio, D. Cancer and cell differentiation: a model to explain malignancy. J. Tumor Marker Oncol., 2002, 17, 47-54.
75. Biava, P. M.; Bonsignorio, D; Hoxa, M. Cell proliferation curves of different human tumor lines after in vitro treatment with Zebrafish embryonic extracts. J. Tumor Marker Oncol., 2001, 16, 195-202.
76. Biava, P. M.; Carluccio, A. Activation of anti-oncogene p53 produced by embryonic extracts in vitro tumor cells. J. Tumor Marker Oncol., 1997, 12, 9-15. (Pubitemid 127806874)
77. Biava, P. M.; Bonsignorio, D.; Hoxa, M.; Facco, R.; Ielapi, T.; Frati, L.; Bizzarri, M. Post-traslational modification of the retinoblastoma protein (pRb) induced by in vitro administration of Zebrafish embryonic extracts on human kidney adenocarcinomacell line. J. Tumor Marker Oncol., 2002, 17, 59-64.
78. Cucina, A.; Biava, P. M.; D'Anselmi, F.; Coluccia, P.; Conti, F.; Di Clemente, R.; Miccheli, A.; Frati, L. Gulino, A; Bizzarri, M. Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). Apoptosis, 2006, 9, 1617-1628. (Pubitemid 44253678)
79. D'Anselmi, F.; Cucina, A.; Biava, P. M. Proietti, S. Coluccia, P; Frati, L; Bizzarri, M. Zebrafish stem cell differentiation stage factors suppress Bcl-xL release and enhance 5 Fu mediated apoptosisin colon cancer cells. Curr. Pharm. Biotechnol., 2011, 12, 261-267.
80. Biava, P. M.; Bonsignorio, D.; Impagliazzo, M.; Frosi, A.; Larese, F.; Negro, C.; Hermann, G. F.; Matarese, S.; Malzac, J.; Pontiggia, P. Embryonic differentiation factors with anticancer properties: preliminary clinical results in the therapy for advanced tumors. J. Tumor Marker Oncol., 2002, 17, 65-69.
81. Livraghi, T.; Meloni, F.; Frosi, A.; Lazzaroni, S.; Bizzarri, M.; Frati, L.; Biava, P. M. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol. Res., 2005, 15, 399-408. (Pubitemid 43198597)
82. Livraghi, T.; Ceriani, R.; Palmisano, A.; Pedicini, V.; Pich, M. G.; Tommasini, M. A.; Torzilli, G. Complete response in 5 out of 38 patients with advanced hepatocellular carcinoma treated with stem cell differentiation stage factors: case reports from a single centre. Curr. Pharm. Biotechnol., 2011, 12, 254-260.
83. Whiteside, T. L. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem. Soc. Trans., 2013, 41, 245-251.
84. Sun, Y.; Campisi, J.; Higano, C.; Beer, T. M.; Porter, P.; Coleman, I.; True, L.; Nelson, P. S. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Med., 2012, 18, 1359-1368.
85. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rébé, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cell infiltrating the tumor. Cancer Res., 2010, 70, 3052-3061.